News & Updates

Monthly dosing of the anti-PCSK9 small binding protein lerodalcibep appears to significantly reduce low-density lipoprotein cholesterol (LDL-C) in patients with cardiovascular disease (CVD) or at high risk of atherosclerotic CVD who are unable to achieve target LDL-C levels while receiving maximal tolerated statins alone, according to the phase III LIBERATE-HR trial.

A registry-based cohort study presented at ERS 2024 demonstrates a relationship between antibiotic exposure in early life and the development of immune-mediated diseases (IMDs) in childhood and young adulthood.

Cannabinoids for medical purposes in children and adolescents have been linked to increased risk of adverse events (AEs), according to the results of a meta-analysis.

The use of a recombinant zoster vaccine (RZV) significantly lowers the risk of developing herpes zoster in older adults aged ≥65 years compared with placebo, according to a study presented at WONCA 2024.

Serum potassium levels in Chinese patients with hyperkalemia appears to decrease following treatment with sodium zirconium cyclosilicate (SZC), as shown in the results of a phase III trial.

Adding once-daily subcutaneous liraglutide to lifestyle interventions reduces BMI in children aged 6 to <12 years with obesity, according to the SCALE Kids trial presented at EASD 2024.

In a dose-ranging study presented at ERS 2024, the carbonic anhydrase inhibitor sulthiame (STM), an anticonvulsant, reduced sleep-disordered breathing and improved sleep quality, hypoxia, and daytime sleepiness in individuals with obstructive sleep apnoea (OSA).